Meet a Researcher: Dr Rachel Taylor
Dr Rachel Taylor is part of the UK Inherited Retinal Dystrophy Consortium (UKIRDC) team at the University of Manchester.
Search
Search results
From isolation to exploration
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
From isolation to exploration: what you can do to build your confidence when travelling
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
RECORDING: Annual Conference – 28 September 2024
A recording of the Retina UK Annual Conference on 28 September 2024. The Conference was held at the Pendulum Hotel in Manchester and online.
RECORDING: Professionals’ Conference – 8 July 2022
A recording of the Retina UK Professionals' Conference on 8 July 2022. The Conference was held at the Macdonald Burlington Hotel in Birmingham and also online.
Information for employers
If you are considering employing someone with inherited sight loss, or have an employee recently been diagnosed with the condition, you will need to take steps to ensure that you treat them fairly and that they can work safely and effectively.
Information for teachers
If you have a child with a visual impairment joining your class, you may have questions about how best you can teach and help them.
One-Year Survival of Transplanted Cells Marks Progress in Early Retinal Regeneration Studies
Researchers have recently presented promising clinical data at the International Society for Stem Cell Research demonstrating that transplanted human neural progenitor cells survived for at least one year in participants with Retinitis Pigmentosa (RP).
Atsena Therapeutics present positive clinical data for LCA1 gene therapy program
Astena Theraputics' investigational gene therapy, ATSN-101, has shown promising long-term results in an early clinical trial for LCA1, a sever inherited retinal disease caused by mutations in the GUCY2D gene.
Renewed Momentum for XLRP: MeiraGTx Targets Rapid Approval Path for bota-vec following reacquisition from Johnson and Johnson
It has recently been announced that Meira-GTx, who originally developed bota-vec and collaborated with J&J during its early clinical trials, have entered into an asset purchase agreement with J&J to acquire bota-vec and progress the program towards global regulatory filings for approval.